RIPK1-IN-33 is an orally active RIPK1 inhibitor with excellent blood-brain barrier permeability, exhibiting an IC50 of 0.115 µM. It demonstrates significant anti-ferroptosis activity, radical scavenging capability (IC50= 123.3 µM), and anti-lipid peroxidation effects (IC50= 9.72 µM). In transient middle cerebral artery occlusion (tMCAO) models, it significantly reduces cerebral infarct volume and improves neurological scores. RIPK1-IN-33 is suitable for ischemic stroke research.
Target:
RIP kinase|||Ferroptosis
* VAT and and shipping costs not included. Errors and price changes excepted
